Search
Latamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseRevumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalMenin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of _HOXA_ expression and leukemogenesis. … [L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376]
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedAs patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Products: Nuwiq 250IU Powder for Solution for Injection, Nuwiq 500IU Powder for Solution for InjectionEquine Botulinum Neurotoxin E Immune FAB2
go.drugbank.com/drugs/DB13897ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients. … Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E.
Equine Botulinum Neurotoxin C Immune FAB2
go.drugbank.com/drugs/DB13898ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients. … Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C.
Patisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].
Categories: Compounds used in a research, industrial, or household settingPostoperative paralytic ileus
go.drugbank.com/conditions/DBCOND0025693Drugs: TrimebutineSynonyms: Post-Operative Ileus (POI)Romosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalIn a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant
Categories: Drugs for Treatment of Bone DiseasesProducts: EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML, EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105MG/1.17MLLebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalyears and older with a body weight of at least 40 kg. … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].
Categories: Agents for Dermatitis, Excluding CorticosteroidsUdenafil
go.drugbank.com/drugs/DB06267ApprovedIt is not yet approved for use in the U.S., E.U., or Canada. … Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.